Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States
About Illuccix(R) Telix's lead investigational product, Illuccix(R) (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix(R) in the European Union and Canada. None of Telix's products have received a marketing authorisation in any jurisdiction.
Eckert & Ziegler AG Contact: Karolin Riehle, Investor Relations Robert-R?ssle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, firstname.lastname@example.org, www.ezag.com
Telix Pharmaceuticals Contact: Dr. Stewart Holmstrom, Investor Relations Suite 401, 55 Flemington Road, North Melbourne, VIC 3051, Australia Email: email@example.com
03.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-R?ssle-Str.10 13125 Berlin
Germany Phone: +49 30 941084-138 Fax: +49 30 941084-112 E-mail: firstname.lastname@example.org Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1203887 ? End of News DGAP News Service